Alvotech AVT80 Progress And Sandoz Deals Shape Biosimilar Outlook

Simply Wall St

Mon, February 16, 2026 at 6:08 PM GMT+9 4 min read

In this article:

ALVO

-1.49%

SDZNY

-0.28%

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

Alvotech (NasdaqGM:ALVO) reported positive clinical trial results for AVT80, its biosimilar candidate to Entyvio.

The company also signed supply and commercialization agreements with Sandoz covering Canada, Australia, and New Zealand.

These developments relate to a key biosimilar targeting a blockbuster inflammatory bowel disease treatment and expand Alvotech’s commercial reach.

Alvotech focuses on developing and manufacturing biosimilars, an area that sits at the intersection of cost pressure in healthcare and patent expiry for large biologic drugs. AVT80 targets Entyvio, a reference therapy widely used in conditions such as ulcerative colitis and Crohn’s disease, which keeps investor attention on how biosimilars might influence pricing and market share across this category.

For readers tracking NasdaqGM:ALVO, the AVT80 data and the new Sandoz agreements are likely to play a role in how the company frames its pipeline and partnership model over the coming years. The combination of clinical progress with broader distribution rights provides more concrete milestones to watch, including regulatory filings, launch timing, and how Alvotech positions itself in global biosimilar competition.

Stay updated on the most important news stories for Alvotech by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Alvotech.

NasdaqGM:ALVO Earnings & Revenue Growth as at Feb 2026

📰 Beyond the headline: 3 risks and 4 things going right for Alvotech that every investor should see.

For Alvotech, the AVT80 pharmacokinetic success and the Sandoz agreements point to two key angles that matter to investors: product risk and route to market. The AVT80 trial met its primary endpoints for similarity to Entyvio on drug exposure, safety, tolerability, and immune response in healthy volunteers, which helps reduce early clinical risk for a future biosimilar in inflammatory bowel disease. At the same time, the supply and commercialization deals hand regulatory filings and on-the-ground selling in Canada, Australia, and New Zealand to Sandoz, while Alvotech keeps development and manufacturing. That setup fits a capital-light commercial model, where Alvotech aims to use partners with existing sales infrastructure rather than build its own. From a competitive standpoint, Alvotech is trying to carve out share in a space occupied by players such as Amgen, Pfizer, and Samsung Bioepis, where speed to market, breadth of portfolio, and partner strength often decide who gets on payer formularies.

Story Continues  

How This Fits Into The Alvotech Narrative

The AVT80 data and expanded Sandoz reach support the idea in the narrative that an expanding global rollout and partner network can help Alvotech access large biologic markets as patents expire.

Reliance on partner-led launches, including Sandoz in these territories, also echoes the narrative’s concern about partner concentration, since execution by third parties can influence revenue timing and predictability.

The AVT80 progress and new territories increase pipeline and geographic breadth, which is not fully captured in the narrative’s focus on Humira, STELARA, and European approvals, and may add another layer to how investors think about long-term optionality.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Alvotech to help decide what it’s worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Analysts have flagged high financial risk, including interest costs that are not well covered by earnings and negative shareholders’ equity, which can limit flexibility if product launches are delayed.

⚠️ The AVT80 study is an early PK trial in healthy volunteers, and biosimilarity has not yet been established by regulators, so there is still regulatory and execution risk before any revenue contribution.

🎁 Alvotech is reported to be trading at a large discount to one estimate of fair value and at what is described as good value versus peers and the industry, which some investors may see as room for sentiment to improve if execution continues.

🎁 The company is described as having returned to profitability with earnings forecast by analysts to grow by about 40.82% per year, and news like the AVT80 progress plus new Sandoz territories fits with a growing biosimilar platform.

What To Watch Going Forward

From here, investors will likely watch for follow up AVT80 trials in patient populations, regulatory filing plans in major markets, and any clarity on timelines for biosimilarity opinions. It is also worth tracking how quickly Sandoz moves on submissions in Canada, Australia, and New Zealand, plus any updates on pricing and formulary access once products are approved. Given the earlier regulatory issues mentioned in the narrative, progress on manufacturing reliability and inspection outcomes remains important as Alvotech adds more products and partners.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Alvotech, head to the community page for Alvotech to never miss an update on the top community narratives.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include ALVO.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info